Equities Analysts Offer Predictions for TEVA FY2025 Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Stock analysts at Zacks Research upped their FY2025 earnings per share (EPS) estimates for shares of Teva Pharmaceutical Industries in a research report issued to clients and investors on Thursday, April 3rd. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $2.48 for the year, up from their prior estimate of $2.42. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' Q4 2025 earnings at $0.69 EPS, Q2 2026 earnings at $0.62 EPS, Q3 2026 earnings at $0.80 EPS, Q4 2026 earnings at $0.71 EPS, FY2026 earnings at $2.62 EPS and FY2027 earnings at $2.82 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%.

Several other analysts have also issued reports on TEVA. UBS Group cut their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Bank of America reduced their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. Barclays decreased their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Friday, April 4th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $23.43.

Remove Ads

Teva Pharmaceutical Industries Stock Up 4.7 %

Shares of NYSE:TEVA traded up $0.60 during trading on Monday, reaching $13.42. 12,222,912 shares of the company traded hands, compared to its average volume of 9,938,997. The firm has a fifty day simple moving average of $15.79 and a 200 day simple moving average of $17.82. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries has a 1-year low of $12.47 and a 1-year high of $22.80. The firm has a market cap of $15.22 billion, a P/E ratio of -9.26, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72.

Institutional Trading of Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently modified their holdings of TEVA. Oarsman Capital Inc. bought a new position in Teva Pharmaceutical Industries in the 4th quarter worth $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth about $44,000. Wilmington Savings Fund Society FSB bought a new position in shares of Teva Pharmaceutical Industries in the third quarter worth about $50,000. Ameliora Wealth Management Ltd. acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $66,000. Finally, Versant Capital Management Inc boosted its stake in Teva Pharmaceutical Industries by 437.8% during the 1st quarter. Versant Capital Management Inc now owns 5,297 shares of the company's stock valued at $81,000 after purchasing an additional 4,312 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.